Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Williams Rosemary Y.
 2. Date of Event Requiring Statement (Month/Day/Year)
08/16/2018		 3. Issuer Name and Ticker or Trading Symbol
BELLICUM PHARMACEUTICALS, INC [BLCM]
(Last)
(First)
(Middle)
C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Principal Accounting Officer
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

HOUSTON, TX 77030		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 3,186
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   (1) 04/30/2024 Common Stock 17,647 $ 2.55 D  
Stock Option (right to buy)   (2) 10/27/2024 Common Stock 11,764 $ 7.47 D  
Stock Option (right to buy)   (3) 02/23/2025 Common Stock 14,000 $ 23.47 D  
Stock Option (right to buy)   (4) 01/03/2026 Common Stock 15,000 $ 19 D  
Stock Option (right to buy)   (5) 01/02/2027 Common Stock 5,625 $ 13.89 D  
Stock Option (right to buy)   (6) 07/02/2027 Common Stock 13,125 $ 11.7 D  
Stock Option (right to buy)   (7) 01/01/2028 Common Stock 9,225 $ 9.23 D  
Stock Option (right to buy)   (8) 07/01/2028 Common Stock 21,525 $ 7.72 D  
Restricted Stock Units   (9)   (9) Common Stock 2,344 $ (10) D  
Restricted Stock Units   (11)   (11) Common Stock 5,125 $ (10) D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Williams Rosemary Y.
C/O BELLICUM PHARMACEUTICALS, INC.
2130 W. HOLCOMBE BLVD., STE. 800
HOUSTON, TX 77030		       Principal Accounting Officer  

Signatures

Rosemary Y. Williams 01/04/2019
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) 25% of the shares subject to the stock option vest and become exercisable on May 1, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
(2) 25% of the shares subject to the stock option vest and become exercisable on October 28, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
(3) 25% of the shares subject to the stock option vest and become exercisable on February 24, 2016, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
(4) 25% of the shares subject to the stock option vest and become exercisable on January 4, 2017, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
(5) 25% of the shares subject to the stock option vest and become exercisable on January 3, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
(6) 25% of the shares subject to the stock option vest and become exercisable on July 03, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
(7) 25% of the shares subject to the stock option vest and become exercisable on January 2, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
(8) 25% of the shares subject to the stock option vest and become exercisable on July 02, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
(9) On January 3, 2017, the reporting person was granted restricted stock units (the "RSUs") for 3,125 shares. The RSUs vest in four annual installments beginning on January 3, 2018.
(10) Each RSU represents a contingent right to receive one share of the Issuer common stock.
(11) On January 2, 2018, the reporting person was granted the RSUs for 5,125 shares. The RSUs vest in four equal annual installments beginning on January 2, 2019.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.